Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors.

doi:10.1128/AAC.47.2.759-769.2003

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors.

Antimicrobial agents and chemotherapy - 1 Feb 2003

Watkins Terri, Resch Wolfgang, Irlbeck David, Swanstrom Ronald

Abstract excerpt

Protease inhibitors represent some of the most potent agents available for therapeutic strategies designed to inhibit human immunodeficiency virus type 1 (HIV-1) replication. Under certain circumstances the virus develops resistance to the inhibitor, thereby negating the benefits of this therapy. We have carried out selections for high-level resistance to each of three protease inhibitors (indinavir, ritonavir,...

Topics

Cells, Cultured
Drug Resistance, Viral
HIV Protease
HIV Protease Inhibitors
HIV-1
Indinavir
Mutation
Ritonavir
Saquinavir

Source

Open in PubMed Open full text

Identifiers

PMID: 12543689
DOI: 10.1128/AAC.47.2.759-769.2003
PMCID: PMC151730

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics